PH12021552829A1 - T cell manufacturing compositions and methods - Google Patents

T cell manufacturing compositions and methods

Info

Publication number
PH12021552829A1
PH12021552829A1 PH1/2021/552829A PH12021552829A PH12021552829A1 PH 12021552829 A1 PH12021552829 A1 PH 12021552829A1 PH 12021552829 A PH12021552829 A PH 12021552829A PH 12021552829 A1 PH12021552829 A1 PH 12021552829A1
Authority
PH
Philippines
Prior art keywords
cell
methods
cell manufacturing
manufacturing compositions
antigen specific
Prior art date
Application number
PH1/2021/552829A
Other languages
English (en)
Inventor
Noor Bakker
Flavian Duvalle Brown
Boer Renate De
Jessica Kohler
Christina Murphy Kuksin
Divya Reddy Lenkala
Ton Schumacher
Buuren Marit M Van
Den Berg Joost Huibert Van
Original Assignee
Biontech Us Inc
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc, Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis filed Critical Biontech Us Inc
Publication of PH12021552829A1 publication Critical patent/PH12021552829A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Moulding By Coating Moulds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
PH1/2021/552829A 2019-05-08 2020-05-07 T cell manufacturing compositions and methods PH12021552829A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845251P 2019-05-08 2019-05-08
PCT/US2020/031898 WO2020227546A1 (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods

Publications (1)

Publication Number Publication Date
PH12021552829A1 true PH12021552829A1 (en) 2023-01-16

Family

ID=73051205

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552829A PH12021552829A1 (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods

Country Status (15)

Country Link
US (1) US20220280621A1 (https=)
EP (1) EP3965784A4 (https=)
JP (2) JP7582971B2 (https=)
KR (2) KR102756321B1 (https=)
CN (2) CN121086984A (https=)
AR (1) AR118859A1 (https=)
AU (1) AU2020268397A1 (https=)
BR (1) BR112021022363A2 (https=)
CA (1) CA3137037A1 (https=)
IL (1) IL287874A (https=)
MX (1) MX2021013608A (https=)
PH (1) PH12021552829A1 (https=)
SG (1) SG11202112346WA (https=)
TW (2) TWI777160B (https=)
WO (1) WO2020227546A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
EP4114400A4 (en) * 2020-03-05 2023-10-18 Exuma Biotech Corp. Methods and compositions for the delivery of modified lymphocyte aggregates
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
US20230374455A1 (en) * 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
US11948694B2 (en) * 2021-05-12 2024-04-02 Merative Us L.P. Controlling compartmental flows in epidemiological modeling based on mobility data
US12062456B2 (en) 2021-05-27 2024-08-13 Merative Us L.P. Hypothetical scenario evaluation in infectious disease dynamics based on similar regions
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
IL321246A (en) * 2022-12-09 2025-08-01 Biontech Us Inc Compositions and methods for producing T cells
WO2024151124A1 (ko) * 2023-01-12 2024-07-18 주식회사 이뮤노맥스 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
EP2749639B1 (en) * 2012-02-10 2016-10-12 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
RU2763795C2 (ru) * 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
DE102015214780A1 (de) * 2015-08-03 2017-02-09 Continental Automotive Gmbh Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems
AU2016306408B2 (en) * 2015-08-10 2021-02-11 Toray Industries, Inc. Immune inducer
EP3347051A4 (en) * 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
WO2017059557A1 (en) * 2015-10-09 2017-04-13 Peking University Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
AU2018337960B2 (en) * 2017-09-20 2025-08-14 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
CA3081840A1 (en) * 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法

Also Published As

Publication number Publication date
MX2021013608A (es) 2022-01-31
KR20240161214A (ko) 2024-11-12
CN121086984A (zh) 2025-12-09
AU2020268397A1 (en) 2022-01-06
AR118859A1 (es) 2021-11-03
EP3965784A4 (en) 2023-06-21
SG11202112346WA (en) 2021-12-30
CN114096261B (zh) 2025-09-26
BR112021022363A2 (pt) 2022-03-22
EP3965784A1 (en) 2022-03-16
KR20220044242A (ko) 2022-04-07
KR102756321B1 (ko) 2025-01-16
CN114096261A (zh) 2022-02-25
WO2020227546A1 (en) 2020-11-12
TW202248419A (zh) 2022-12-16
US20220280621A1 (en) 2022-09-08
JP2024038503A (ja) 2024-03-19
JP2022531474A (ja) 2022-07-06
IL287874A (en) 2022-01-01
TWI777160B (zh) 2022-09-11
JP7582971B2 (ja) 2024-11-13
CA3137037A1 (en) 2020-11-12
TW202108761A (zh) 2021-03-01
TWI867324B (zh) 2024-12-21

Similar Documents

Publication Publication Date Title
PH12021552829A1 (en) T cell manufacturing compositions and methods
WO2019094642A8 (en) T cell manufacturing compositions and methods
MX2023001815A (es) Metodos y composiciones de fabricacion de celulas t.
MX2025005315A (es) Celulas t para usarse en el tratamiento de una enfermedad o afeccion
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
WO2020092848A3 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2023014187A (es) Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa.
MX2020009773A (es) Terapia de combinacion.
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
PH12012501681A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
MX2019012465A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
ZA202304965B (en) Combination therapy for treating cancer
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
PH12023552792A1 (en) Combination therapies for the treatment of cancer
WO2020000035A8 (en) Modified t cells and uses thereof
MX2021015401A (es) Terapia de combinacion que comprende un conjugado de farmacoanticuerpo anti-cd25 y otro agente.
PH12022551078A1 (en) Combination therapy to treat brain cancer
MX2021013351A (es) Terapias de combinacion.
PH12021550376A1 (en) Combination therapy
PH12021550035A1 (en) Combination therapy
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same